Phase III trial
-
One Tumor, One Vaccine: The Phase III Checkpoint Behind Personalized Cancer Treatment
On August 19, the individualized mRNA cancer vaccine Intismeran autogene hit its primary endpoint in a Phase III melanoma trial. The milestone is not biology…